HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ConsumerLab iron tests finish up strong

This article was originally published in The Tan Sheet

Executive Summary

All 15 iron supplements evaluated by online testing firm were found to contain iron amounts listed on the label with acceptable lead levels and disintegration qualities necessary for absorption, ConsumerLab announces July 26. Four products under the Sundown Benefits, Puritan's Pride and Vitamin World brands were submitted voluntarily for testing, while ConsumerLab.com selected the 11 other products for certification. Results of the sample were an improvement over a 2001 test in which 17 of 19 iron supplements passed (1"The Tan Sheet" Oct. 8, 2001, In Brief)...

You may also be interested in...



ConsumerLab.com

Seventeen of 19 iron supplements pass tests for label accuracy, disintegration rate and lead levels, online firm announces Oct. 3. Passing products included SmithKline Beecham's Feosol Ferrous Sulfate (65 mg), Novartis' Slow Fe Slow Release Iron (50 mg) and Twinlab's eponymous Iron Caps (18 mg). One failing product, which was marketed specifically to women, "contained lead at a level in excess of .5 mcg per daily serving," while another contained only 19.7 mg of claimed 27 mg on the label. ConsumerLab expects to release nutrition bar results later this month

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS128081

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel